ClinicalTrials.gg
Status unknownNCT02918123Updated Mar 14, 2018

Safety of FURESTEM-CD Inj. in Patients With Moderate to Severe Plaque-type Psoriasis

A Phase 1 interventional study of FURESTEM-CD Inj. in Psoriasis, sponsored by Kang Stem Biotech Co., Ltd.. Status unknown at 1 site in Korea, Republic of. Open to participants aged 19 Years to 65 Years. Per ClinicalTrials.gov, last updated 2018-03-14.

Sponsored by Kang Stem Biotech Co., Ltd. · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2018), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
19 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 70 studies in Psoriasis with a site in Korea, Republic of — 5 open to participants now, 13 under way, 9 of them phase 3. Psoriasis · Korea, Republic of.

Planned enrollment
58th of 60
9 · median 457
Started
2018
with 7 others
Phase 1
3 of 70
none open now
Registered
23rd of 70
by date

Among the 70 studies in Psoriasis with a site in Korea, Republic of, this one is the 58th largest by planned enrollment of the 60 interventional ones that give a count, is one of 8 that started in 2018, is one of 3 in phase 1, and was the 23rd registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 70 studies in Psoriasis with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 19 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Psoriasis with a site in Korea, Republic of, or all of them as a file.
02

Study summary

Phase I clinical trial to evaluate safety of FURESTEM-CD Inj. in patients with moderate to severe in plaque-type psoriasis injection for 4weeks.

Read the detailed description

This is a phase 1, single center, randomized, open label, study of safety of FURESTEM-CD Inj. in subjects with moderate to severe plaque psoriasis.

Approximately 9\~18 subjects will be administrated FURESTEM-CD Inj.

FURESTEM-CD Inj. is composed of allogeneic hUCB-MSC(human Umbilical Cord Blood derived-Mesenchymal Stem cell). hUCB-MSCs are mesenchymal stem cells from umbilical cord blood. Mesenchymal stem cells are well-known for immunosuppression, anti-inflammatory ability and capable of differentiating into a wide range of cell types. Therefore, FURSTEM-CD Inj. has huge possibility as cell therapy products for plaque-type Psoriasis patients.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • Psoriasis
  • Plaque psoriasis
  • Stem cell
  • Cell therapy
  • Furestem
  • Mesenchymal stem cell
  • MSC
  • Umbilical cord blood
  • hUCB-MSC
  • UCB-MSC
04

Who can participate

Ages eligible
19 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 19-65 years old(both sexes)
  2. Have been diagnosed with plaque-type psoriasis at least 6 months prior to screening (subjects with concurrent psoriatic arthritis[PsA] may be enrolled)
  3. Psoriasis Area and Severity Index (PASI) score >= 12 at screening
  4. BSA(Body Surface Area) >= 10 percentage at screening
  5. Have had at least one of the following conventional systemic agent for the treatment of psoriasis,

    • MTX, Cyclosporine, Photochemotherapy, TNF-alpha inhibitor or IL-12/IL-23 inhibitor
  6. Subject who would agree to avoid prolonged sun exposure, use of tanning booths or other ultraviolet light sources during the clinical study
  7. Subject who understands and voluntarily signs the form

Exclusion criteria

Exclusion Criteria:

  1. Subject who has other types of psoriasis (eg. Erythrodermic, guttate, or pustular)
  2. Have a history of chronic or recurrent infectious disease
  3. Have received phototherapy or any systemic medications/treatments within 4 weeks of screening that could affect psoriasis or PASI evaluation
  4. Have used topical medications/treatments within 2 weeks of screening that could affect psoriasis or PASI evaluation
  5. Have used any systemic within 4 weeks of screening
  6. Have been administered with the following biological agents that could affect plaque-type psoriasis

    • Etanercept - within 4 weeks of screening
    • Adalimumab, alefacept, infliximab - within 2 months of screening
    • Ustekinumab - within 4 weeks of screening
    • Other biological agents - within 4 weeks of screening/five half-lives(whichever was longer)
  7. Pregnant, breast-feeding women or women who plan to become pregnant during this study (Females of must have a negative urine pregnancy test at screening)
  8. Have been administered any types of investigational drugs within the previous 4 weeks or five half-lives of the investigational agent, whichever is longer
  9. Subject who already took or need to take medicine which is prohibited during the clinical study
  10. Subject who has sever dyshepatia (Creatinine value ≥ 2X at screening test)
  11. Subject who has severe renal dysfunction (/ALT value ≥ 2X Upper limit of the normal range at screening test)
  12. Have received a live viral or bacterial vaccination within 3 months of screening
  13. Have had a BCG(Bacillus Calmette-Guérin) vaccination within 12 months of screening
  14. Have a transplanted organ(with the exception of a corneal transplant > 3 months prior to screening)
  15. Have any known or have a history of malignancy
  16. Have a history of , heavy metal poisoning etc. to drugs which are composed of similar components or have undergone allergy immunotherapy previously for prevention of anaphylactic reactions
  17. Have had a serious infection (eg. Sepsis, pneumonia or pyelonephritis), or have been hospitalized or received IV antibiotics for an infection during the 2 months prior to screening
  18. Positive for virus(HBV) surface antigen or anti- virus antibody screening
  19. Known to have had a substance abuse(drug or alcohol) problem within 12 months of screening
  20. Subject who experienced stem cell therapy
  21. Any other conditions which the PI suspect the patient to be unsuitable for the clinical
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    Treatment

    1. FURESTEM-CD Inj. 5.0x10\^7 cells 2. FURESTEM-CD Inj. 1.0x10\^7 cells 3. FURESTEM-CD Inj. 2.0x10\^8 cells

    Biological: FURESTEM-CD Inj.

Interventions

  • Patients will be treated FURESTEM-CD Inj. Subcutaneous injection

    Also known as: hUCB-MSCs

06

What researchers measure

Primary outcomes

  1. number of adverse events

    Time frame: 4 weeks follow-up after treatment

  2. safety lab tests, physical examination, ECG, vital signs

    Time frame: 4 weeks follow-up after treatment

  3. variation of Cytokine, PASI, BSA

    Time frame: 4 weeks follow-up after treatment

Other outcomes

  1. number of adverse events, safety lab tests, physical examination, vital signs

    Time frame: 144 weeks follow-up after treatment (Extension study)

07

Study locations

1 of 1 sites recruiting
  • The Catholic Univ. Korea Seoul, St. Marry's Hospital
    Seoul, 06591, Korea, Republic of
    Recruiting
    • Tae-yoon Kim · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2018 (actual). Primary completion is estimated for Dec 2021, 47 months after the start.

Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's planned 47 months is above that.

Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2016
First posted
Sep 28, 2016
StartActual
Jan 17, 2018
Primary completionEst.
Dec 2021
CompletionEst.
Dec 2021
Last update
Mar 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02918123
Lead sponsor
Kang Stem Biotech Co., Ltd.
Responsible party
Sponsor
First posted
Sep 28, 2016
Start date
Jan 17, 2018
Primary completion
Dec 2021 (estimated)
Completion
Dec 2021 (estimated)
Last update
Mar 14, 2018

Study contacts

Eunji Kang
Contact
ejkang@kangstem.com
82-2-2036-7533
Taeyoon Kim
principal investigator · Seoul St. Mary's Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Stem Cell

Start the discussion